Literature DB >> 17587309

Hyperammonaemia alters the mechanisms by which metabotropic glutamate receptors in nucleus accumbens modulate motor function.

Omar Cauli1, Nisrin Mlili, Regina Rodrigo, Vicente Felipo.   

Abstract

Activation of metabotropic glutamate receptors by injecting (S)3,5-dihydroxyphenylglycine (DHPG) in nucleus accumbens (NAcc) increases motor activity by different mechanisms in control rats and in rats with chronic liver failure due to portacaval shunt. In control rats DHPG increases extracellular dopamine in NAcc and induces locomotion by activating the 'normal' circuit: NAcc-->ventral pallidum-->medial-dorsal thalamus-->prefrontal cortex, which is not activated in portacaval shunt rats. In these rats, DHPG activates an 'alternative' circuit: NAcc-->substantia nigra pars reticulata-->ventro-medial thalamus-->prefrontal cortex, which is not activated in control rats. The reasons by which liver failure leads to activation of this 'alternative' circuit remain unclear. The aim of this work was to assess whether hyperammonaemia could be responsible for the alterations found in chronic liver failure. We injected DHPG in NAcc of control or hyperammonaemic rats and analysed, by in vivo brain microdialysis, the neurochemical responses of the 'normal' and 'alternative' circuits. In hyperammonaemic rats DHPG injection in NAcc activates both the 'normal' and 'alternative' circuits. In hyperammonaemia, activation of the 'alternative' circuit and increased motor response following metabotropic glutamate receptors activation in NAcc seem due to an increase in extracellular glutamate which activates AMPA receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587309     DOI: 10.1111/j.1471-4159.2007.04734.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

Review 1.  Chronic hyperammonemia, glutamatergic neurotransmission and neurological alterations.

Authors:  Marta Llansola; Carmina Montoliu; Omar Cauli; Vicente Hernández-Rabaza; Ana Agustí; Andrea Cabrera-Pastor; Carla Giménez-Garzó; Alba González-Usano; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2012-09-26       Impact factor: 3.584

2.  Absence of neuropsychological impairment in hyperammonaemia in healthy young adults; possible synergism in development of hepatic encephalopathy (HE) symptoms?

Authors:  Daniel J Wilkinson; Nicholas J Smeeton; Paul C Castle; Peter W Watt
Journal:  Metab Brain Dis       Date:  2011-07-20       Impact factor: 3.584

Review 3.  Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy.

Authors:  Omar Cauli; Regina Rodrigo; Marta Llansola; Carmina Montoliu; Pilar Monfort; Blanca Piedrafita; Nisrin El Mlili; Jordi Boix; Ana Agustí; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

4.  Synergistic effects between CA1 mu opioid and dopamine D1-like receptors in impaired passive avoidance performance induced by hepatic encephalopathy in mice.

Authors:  Mohammad Nasehi; Samaneh Amin Yavari; Mohammad Reza Zarrindast
Journal:  Psychopharmacology (Berl)       Date:  2013-02-13       Impact factor: 4.530

5.  Presence of diadenosine polyphosphates in microdialysis samples from rat cerebellum in vivo: effect of mild hyperammonemia on their receptors.

Authors:  Javier Gualix; Rosa Gómez-Villafuertes; Jesús Pintor; Marta Llansola; Vicente Felipo; M Teresa Miras-Portugal
Journal:  Purinergic Signal       Date:  2013-08-13       Impact factor: 3.765

6.  Hyperammonemia alters membrane expression of GluA1 and GluA2 subunits of AMPA receptors in hippocampus by enhancing activation of the IL-1 receptor: underlying mechanisms.

Authors:  Lucas Taoro-Gonzalez; Yaiza M Arenas; Andrea Cabrera-Pastor; Vicente Felipo
Journal:  J Neuroinflammation       Date:  2018-02-08       Impact factor: 8.322

Review 7.  GPCR-Based Dopamine Sensors-A Detailed Guide to Inform Sensor Choice for In vivo Imaging.

Authors:  Marie A Labouesse; Reto B Cola; Tommaso Patriarchi
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.